Johnson & Johnson says nipocalimab approved in China
SHANGHAI, May 21 (Reuters) - Johnson & Johnson's ( JNJ ) nipocalimab has won approval in China, the U.S. drugmaker said on its WeChat social media account Thursday. (Reporting by Andrew Silver in Shanghai Editing by Tomasz Janowski)
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Fidelity The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments